Toxity is higher in patients receiving adjuvant docetaxel without hormonal treatment after radical prostatectomy for high risk cancer- an initial report from the SPCG 12 study
- G Ahlgren (Contributor)
- P F Flodgren (Contributor)
- Tammela, T. (Contributor)
- Kellokumpu-Lehtinen, P. (Contributor)
- L Sengelöv (Contributor)
- M Borre (Contributor)
- A Angelsen (Contributor)
- J R Iversen (Contributor)
Aktiviteetti: Konferenssiesitelmä